✨ Unlock Unlimited Data Exports & Disclosures Access with Tracenable Pro. Learn More →

Medipal Holdings Corp

Common Name
Medipal Holdings
Country
Japan
Sector
Healthcare
Industry
Medical Distribution
Employees
13,061
Ticker
7459
Exchange
TOKYO STOCK EXCHANGE
Description
Medipal Holdings Corp is a leading company in Japan's pharmaceutical distribution industry. As a comprehensive pharmaceutical wholesaler, its primary function is to ensure the efficient distribution a...

Medipal Holdings's GHG Emissions Data Preview

In 2024, Medipal Holdings completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Medipal Holdings has also provided a category-level breakdown for 8 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)202420232022
2021 - 2017
Total Scope 1
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Total Scope 2
Unspecified Calculation Method
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
a
0000000
Total Scope 3
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Limited Data Preview
You are viewing a limited preview of Medipal Holdings’s GHG emissions dataset. The full dataset, available for download, includes Scope 1, 2, and 3 emissions with detailed category-level breakdowns, historical coverage back to 2019, and revenue-based intensity metrics for each scope.
Unrestricted Access to Data and Sources
pro
Remove manual data sourcing from your workflow. Upgrade to Tracenable Pro for unrestricted access to datasets and disclosures across 8,500+ companies with over 10 years of historical coverage.
Download complete datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace values back to original sources
Formats Included
Excel
CSV
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=7459&reporting_period=2024"

Verified Sources Behind Medipal Holdings’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Medipal Holdings’s data sources below and access millions more through our Disclosure Search.

a. Medipal Holdings's Integrated Report 2024
b. Medipal Holdings's Integrated Report 2022

Insights into Medipal Holdings's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Medipal Holdings amounted to 73,575 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Medipal Holdings decreased by 1.89%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

Medipal Holdings's Scope 1 Emissions Over Time

20192020202120222023202409 k18 k27 k36 ktCO2e-6%-2%-6%-7%+9%
  • Total Scope 1
  • Year-over-Year Change

What are Medipal Holdings's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Medipal Holdings were 31,081 metric tons of CO₂ equivalent (tCO₂e).a

Has Medipal Holdings reduced its Scope 1 emissions over time?

Since 2019, Medipal Holdings's Scope 1 emissions have decreased by 12.21%, reflecting a declining long-term trend in Scope 1 emissions over time.ab

Compared to the previous year (2023), Medipal Holdings's Scope 1 emissions increased by 9.29%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a

What are Medipal Holdings's Scope 2 emissions?

In 2024, Medipal Holdings reported Scope 2 greenhouse gas (GHG) emissions of 42,494 tCO₂e without specifying the calculation method.a

Has Medipal Holdings reduced its Scope 2 emissions over time?

Since 2019, Medipal Holdings's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have decreased by 19.19%, reflecting a declining long-term trend in Scope 2 emissions over time.ab

Compared to the previous year (2023), Medipal Holdings's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Medipal Holdings's emissions have plateaued with no significant change in its energy consumption footprint.a

What methodology does Medipal Holdings use for Scope 2 reporting?

In 2024, Medipal Holdings reported its Scope 2 emissions using an unspecified methodology.a

Medipal Holdings's Scope 2 Emissions Over Time

201920202021202220232024015 k30 k45 k60 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Medipal Holdings's Value Chain Emissions

In 2024, Medipal Holdings reported 219,650 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2024 disclosure of Medipal Holdings includes a breakdown across 8 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chaina

Medipal Holdings's Scope 3 Emissions Over Time

201920202021202220232024060 k120 k180 k240 ktCO2e+5%-3%+12%+488%-4%
  • Total Scope 3
  • Year-over-Year Change

What are Medipal Holdings's Scope 3 emissions?

In 2024, Medipal Holdings reported total Scope 3 emissions of 219,650 metric tons of CO₂ equivalent (tCO₂e).a

Approximately 91.42% of these emissions originated from upstream activities such as purchased goods and capital goods, while 8.58% came from downstream activities like product use, distribution, and end-of-life treatment.a

Has Medipal Holdings reduced its Scope 3 emissions over time?

Since 2019, Medipal Holdings's Scope 3 emissions have increased by 543.66%, reflecting a rising long-term trend in Scope 3 emissions over time.ab

Compared to the previous year (2023), Medipal Holdings's Scope 3 emissions remained relatively stable, indicating that Medipal Holdings's emissions have plateaued with no significant change in its value chain footprint.a

What categories of Scope 3 emissions does Medipal Holdings disclose?

In 2024, Medipal Holdings reported emissions for 8 out of the 15 Scope 3 categories defined by the GHG Protocol.a

This partial disclosure allows for some insight into the company's indirect impacts.

What are the main sources of Medipal Holdings's Scope 3 emissions?

In 2024, the largest contributors to Medipal Holdings's Scope 3 emissions were:a

  • Capital Goods (Cat. 2): 72,953 tCO₂e (33.21%)
  • Upstream Transportation and Distribution (Cat. 4): 68,622 tCO₂e (31.24%)
  • Employee Commuting (Cat. 7): 41,858 tCO₂e (19.06%)

Medipal Holdings's Scope 3 Emissions by Categories

Employee Commuting(Cat. 7)(19.1%)Capital Goods(Cat. 2)(33.2%)UpstreamTransportation andDistribution(Cat. 4)(31.2%)

Insights into Medipal Holdings’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Medipal Holdings reported Scope 1 greenhouse gas (GHG) emissions of 31,081 tCO₂e and total revenues of USD 23,500 millions. This translates into an emissions intensity of 1.32 tCO₂e per millions USD.a

Medipal Holdings's Scope 1 Emissions Intensity Compared to Peers

102002,00050,0001,000,000Scope 1 Emissions (tCO2e)201001,00010,00050,000Revenues (Millions of USD)PSMNMAs OneYear: 2024Scope 1: 165 tCO2eRevenue: $M 631Scope 1 Intensity: 0.26 tCO2e/$MHisamitsu PharmaceuticalYear: 2022Scope 1: 7,862 tCO2eRevenue: $M 1,040Scope 1 Intensity: 7.56 tCO2e/$MSawai Group HoldingsYear: 2023Scope 1: 19,500 tCO2eRevenue: $M 1,229Scope 1 Intensity: 15.87 tCO2e/$MNihon KohdenYear: 2024Scope 1: 4,155 tCO2eRevenue: $M 1,466Scope 1 Intensity: 2.83 tCO2e/$MPeptiDreamYear: 2023Scope 1: 3,156 tCO2eRevenue: $M 203Scope 1 Intensity: 15.55 tCO2e/$MSundrugYear: 2024Scope 1: 22,197 tCO2eRevenue: $M 4,964Scope 1 Intensity: 4.47 tCO2e/$MSanten PharmaceuticalYear: 2024Scope 1: 17,372 tCO2eRevenue: $M 1,994Scope 1 Intensity: 8.71 tCO2e/$MH.U. Group HoldingsYear: 2024Scope 1: 7,367 tCO2eRevenue: $M 1,565Scope 1 Intensity: 4.71 tCO2e/$MPPPHC HoldingsYear: 2023Scope 1: 15,861 tCO2eRevenue: $M 2,676Scope 1 Intensity: 5.93 tCO2e/$MSSSugi HoldingsYear: 2023Scope 1: 1,531 tCO2eRevenue: $M 4,898Scope 1 Intensity: 0.31 tCO2e/$MOno PharmaceuticalYear: 2024Scope 1: 8,100 tCO2eRevenue: $M 3,319Scope 1 Intensity: 2.44 tCO2e/$MMatsukiyoCocokara & CoYear: 2024Scope 1: 3,764 tCO2eRevenue: $M 6,752Scope 1 Intensity: 0.56 tCO2e/$MChugai PharmaceuticalYear: 2024Scope 1: 51,143 tCO2eRevenue: $M 7,456Scope 1 Intensity: 6.86 tCO2e/$MSuzukenYear: 2024Scope 1: 26,205 tCO2eRevenue: $M 15,759Scope 1 Intensity: 1.66 tCO2e/$MTsuruha HoldingsYear: 2023Scope 1: 3,424 tCO2eRevenue: $M 6,940Scope 1 Intensity: 0.49 tCO2e/$MOtsuka HoldingsYear: 2024Scope 1: 368,733 tCO2eRevenue: $M 14,840Scope 1 Intensity: 24.85 tCO2e/$MMMMedical Data VisionYear: 2024Scope 1: 13 tCO2eRevenue: $M 38Scope 1 Intensity: 0.35 tCO2e/$MAstellas PharmaYear: 2024Scope 1: 52,212 tCO2eRevenue: $M 10,589Scope 1 Intensity: 4.93 tCO2e/$MTsumura & CoYear: 2021Scope 1: 39,385 tCO2eRevenue: $M 1,055Scope 1 Intensity: 37.32 tCO2e/$MDaiichi SankyoYear: 2024Scope 1: 91,836 tCO2eRevenue: $M 10,576Scope 1 Intensity: 8.68 tCO2e/$MNNNippon ShinyakuYear: 2023Scope 1: 4,366 tCO2eRevenue: $M 1,082Scope 1 Intensity: 4.03 tCO2e/$MAlfresa HoldingsYear: 2025Scope 1: 31,360 tCO2eRevenue: $M 19,746Scope 1 Intensity: 1.59 tCO2e/$MKyowa KirinYear: 2024Scope 1: 16,133 tCO2eRevenue: $M 3,157Scope 1 Intensity: 5.11 tCO2e/$MSumitomo PharmaYear: 2024Scope 1: 23,101 tCO2eRevenue: $M 2,077Scope 1 Intensity: 11.12 tCO2e/$MMMMedipal HoldingsYear: 2024Scope 1: 31,081 tCO2eRevenue: $M 23,500Scope 1 Intensity: 1.32 tCO2e/$M

How does Medipal Holdings's GHG emissions intensity compare to its peers?

In 2024, Medipal Holdings reported a Scope 1 emissions intensity of 1.32 tCO₂e per millions USD. Compared to the peer group median of 4.82, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Medipal Holdings rank on GHG emissions intensity within its industry?

In 2024, Medipal Holdings ranked 6 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

Medipal Holdings is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Insights into Medipal Holdings's Total Carbon Footprint

In 2024, Medipal Holdings reported a total carbon footprint of 293,225 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 3.47% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a

The largest contributor to Medipal Holdings's total carbon footprint was Scope 3 emissions, accounting for 74.91% of the company's total carbon footprint, followed by Scope 2 emissions at 14.49%.a

Want Full Access to Medipal Holdings's GHG Emissions Dataset?
Sign Up